High-resolution serum proteomic profiling of Alzheimer disease samples reveals disease-specific, carrier-protein-bound mass signatures

Clinical Chemistry

Volumn 51, Issue 10, 2005, Pages 1946-1954

  Lopez, Mary F ^a   Mikulskis, Alvydas ^a   Kuzdzal, Scott ^a   Bennett, David A ^b   Kelly, Jeremiah ^b   Golenko, Eva ^a   DiCesare, Joseph ^a   Denoyer, Eric ^a   Patton, Wayne F ^a   Ediger, Richard ^a   Sapp, Lisa ^a   Ziegert, Tillmann ^a   Lynch, Christopher ^a   Kramer, Susan ^a   Whiteley, Gordon R ^c   Wall, Michael R ^d   Mannion, David P ^d   Della Cioppa, Guy ^d   Rakitan, John S ^d   Wolfe, Gershon M ^d  

^a PERKINELMER INC   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c SAIC FREDERICK INC   (United States)

^d Predictive Diagnostics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CARRIER PROTEIN; PEPTIDE DERIVATIVE;

ADULT; AFFINITY CHROMATOGRAPHY; AGED; ALZHEIMER DISEASE; BIOINFORMATICS; COHORT ANALYSIS; CONFERENCE PAPER; CONTROLLED STUDY; DIAGNOSTIC TEST; DISEASE MARKER; FEMALE; GENE IDENTIFICATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METHODOLOGY; PARTICLE SIZE; PROTEIN ANALYSIS; PROTEIN STRUCTURE; PROTEOMICS; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; TECHNOLOGY;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MALE; PEPTIDES; PROTEOMICS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 25444515944     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2005.053090     Document Type: Conference Paper

References (27)

1. Conrads TP, Fusaro VA, Ross S, Johann D, Rajapakse V, Hitt BA, et al. High-resolution serum proteomic features for ovarian cancer detection. Endocr Relat Cancer 2004;11:163-78.
2. Niloff JM, Knapp, RC, Schaetzl E, Reynolds C, Bast RC Jr, Ca125 antigen levels in obstetric and gynecologic patients. Obstet Gynecol 1984;64:703-7.
3. Menon U, Jacobs IJ. Recent developments in ovarian cancer screening. Curr Opin Obstet Gynecol 2000;12:39-42.
4. Cohen LS, Escobar PF, Scharm C, Glimco B, Fishman DA. Three-dimensional power Doppler ultrasound improves the diagnostic accuracy for ovarian cancer prediction. Gynecol Oncol 2001;82: 40-8.
5. Ozols RF, Rubin SC, Thomas GM, Robboy SJ. Epithelial ovarian cancer. In: Hoskins WJ, Perez CA, Young RC, eds. Principles and practice of gynecological oncology, 3rd ed. New York: Lippincott, Williams, and Wilkins, 2001:165-82.
6. Zurawski VR, Orjaseter H, Andersen A, Jellum E. Elevated serum CA-125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer. Int J Cancer 1988;42:677-80.
7. Petricoin EF 3rd, Ornstein DK, Paweletz CP, Ardekani A, Hackett PS, Hitt BA, et al. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 2002;94:1576-8.
8. Keetch DW, Catalona WJ, Smith DS. Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol 1994;151:1571-4.
9. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572-7.
10. Petricoin EF, Zoon KC, Kohn EC, Barrett JC, Liotta LA. Clinical proteomics: translating benchside promise into bedside reality. Nat Rev Drug Discov 2002;1:683-95.
11. Liotta LA, Ferrari M, Petricoin E. Clinical proteomics: written in blood. Nature 2003;425:905.
12. Petricoin EF, Rajapakse V, Herman EH, Arekani AM, Ross S, Johann D, et al. Toxicoproteomics: serum proteomic pattern diagnostics for early detection of drug induced cardiac toxicities and cardioprotection. Toxicol Pathol 2004;32(Suppl 1):1-9.
13. Becker S, Cazares LH, Watson P, Lynch H, Semmes OJ, Drake RR, et al. Surfaced-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) differentiation of serum protein profiles of BRCA 1 and sporadic breast cancer. Ann Surg Oncol 2004;11:907-14.
14. Baggerly KA, Morris JS, Edmonson SR, Coomes KR. Signal in noise; evaluating reported reproducibility of serum proteomic tests for ovarian cancer. J Natl Cancer Inst 2005;97:307-9.
15. Zhu W, Wang X, Ma M, Glimm J, Kovach JS. Detection of cancer-specific markers amid massive mass spectral data. Proc Natl Acad Sci U S A 2003;100:14666-71.
16. Liotta LA, Lowenthal M, Conrads TP, Veenstra TD, Fishman DA, Petricoin EF 3rd. Importance of communication between producers and consumers of publicly available experimental data. J Natl Cancer Inst 2005;97:1-5.
17. Mehta AI, Ross S, Lowenthal MS, Fusaro V, Fishman DA, Petricoin EF 3rd, et al. Biomarker amplification by serum carrier protein binding. Dis Markers 2003-2004;19:1-10.
18. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer's disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003;60:1119-22.
19. Wolfson C, Wolfson DB, Asgharian M, M'Lan CE, Ostbye T, Rockwood K, et al. A reevaluation of the duration of survival after the onset of dementia. N Engl J Med 2001;344:1111-6.
20. Kennedy JL, Farrer LA, Andreasen NC, Mayeux R, St George-Hyslop P. The genetics of adult-onset neuropsychiatric disease: complexities and conundra? Science 2003;302:822-6.
21. McKhann G, Drachmann D, Folstein M, Katzman R, Price D, Stadlan E. Clinical diagnosis of Alzheimer's disease. Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44.
22. Frank RA, Galasko D, Hampel H, Hardy J, de Leon MJ, Mehta PD, et al. Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the Biological Markers Working Group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiol Aging 2003;24:521-36.
23. Bennett DA, Wilson RS, Schneider JA, Evans DA, Beckett LA, Aggarwal NT, et al. Natural history of mild cognitive impairment in older persons. Neurology 2002;59:198-205.
24. Bennett DA, Schneider JA, Bienias JL, Evans MD, Wilson RS. Mild cognitive impairment is related to Alzheimer's disease pathology and cerebral infarctions. Neurology 2005;64:835-41.
25. Diamandis EP. Proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? Clin Chem 2003;49: 1272-8.
26. Cottingham K. Clinical proteomics: are we there yet? Anal Chem 2003;75:472A-6A.
27. Kasahara Y, Tsukada Y. New insights and future advances in cancer diagnostics; limitations of conventional tumor markers.; In: Nakamura RM, Grody WW, Wu JT, Nagle RB, eds. Cancer diagnostics; current and future trends. Totowa, NJ: Humana Press, 2004:015-26.